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The Effects of  Venlafaxine and Dexamethasone 
on the Expression of HSP70 in Rat C6 Glioma Cells
ObjectiveaaThe present study aimed to determine the intracellular action of the antidepres-
sant, venlafaxine, in C6 glioma cells using heat shock protein 70 (HSP70) immunocytochem-
istry and HSP70 Western blots; HSP70 is known to be associated with stress and depression. 
MethodsaaThe extent of HSP70 expression was measured after rat C6 glioma cells were 
treated with 1) dexamethasone only, 2) venlafaxine only, 3) simultaneous venlafaxine and 
dexamethasone, or 4) dexamethasone after venlafaxine pretreatment. Dexamethasone (10 
μM, 6 hours) did not affect the level of HSP70 expression relative to control.
ResultsaaShort-term (1 hour) venlafaxine treatment significantly increased the level of HSP 
70 expression. Simultaneous long-term (72 hours) venlafaxine and dexamethasone treatment 
significantly reduced the level of HSP70 expression. Dexamethasone treatment administered 
following long-term (24 and 72 hours) pretreatment with venlafaxine also significantly re-
duced the level of HSP70 expression.
ConclusionaaShort-term treatment with venlafaxine increases the expression of HSP70, 
but prolonged treatment with dexamethasone suppresses the venlafaxine-induced expression 
of HSP70. These findings suggest that HSP70 and dexamethasone play a significant role in 
the pathophysiology of depression.   Psychiatry Investig 2010;7:43-48
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Introduction
During emergencies, there is a dramatic increase in the production of heat shock protein 
(HSP) in all organisms, the function of which is to repair damage.
1 HSP functions as a molec-
ular chaperone bonding to the exposed hydrophobic portions of proteins to prevent their ag-
gregation and to maintain their original conformation. Under nonstressful conditions, HSP 
forms a complex with the transcription factor monomer heat shock transcription factor (HSF), 
which exists in the cytoplasm and the nucleus, by one-to-one bonding. However, in stress-
ful conditions the degree of misfolding among proteins increases in cells, causing HSP to be 
separated from HSF and to bond with the misfolding protein. HSF separates from the HSP 
conglomerate as a trimer, migrates into the nucleus, bonds to the heat shock element located 
in the heat shock gene promoter, and then activates heat shock gene transcription. As a result, 
when the expression of free HSP increases, HSF is separated from the deoxyribonucleic acid 
and contributes as a monomer to the increased formation of the HSP-HSF complex. These 
processes control the expression of HSP.
2
The 70-kDa HSP (HSP70) is known to be associated with the psychopathology of depres-
sion. Depletion of HSP70 messenger ribonucleic acid has been observed in some depressed 
patients, but not in control subjects or in patients with other diseases.
3 HSP70 is also known 
to control the glucocorticoid receptor (GR), which is known to play a role in depression.
4,5
HSP70, which is observed in abundance in healthy cells, also functions as a molecular ch-
aperone under non-stressful conditions. When the cell is exposed to stress, a massive amount 
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Effect of Venlafaxine and Dexamethasone on HSP70
of HSP70 is synthesized in an attempt to maintain the cell’s 
homeostasis.
6,7 HSP70 is the first HSP to be synthesized, and 
is important for the activation of structurally unstable GRs.
4,5 
It has been reported that in major depressive disorders,
3,8 the 
allele-specific abnormal transcription of the HSP70 gene on 
chromosome 6 underlies the altered stress and/or immune re-
sponse, and the functions of antidepressants
9,10 by preventing 
the neurotoxicity of N-methyl-D-aspartate receptor antagonists.
Depressive patients exhibit increased cortisol levels in the 
plasma, urine, and cerebrospinal fluid, a hyperreaction of corti-
sol to adrenocorticotrophic hormone, and hypertrophy of the 
pituitary and adrenal glands.
11-13 The most consistent finding in 
depressed patients is hyperactivity of the hypothalamic-pitu-
itary-adrenal (HPA) axis, as demonstrated using the dexa-
methasone/corticotropin-releasing factor test, which is consid-
ered to be the most sensitive measure of HPA axis hyperacti-
vity.
14 When the concentration of glucocorticoids is kept high 
for a prolonged period of time, symptoms of neurotoxicity de-
velop that are thought to result from the effacement of pyrami-
dal neurons in the hippocampus and atrophy of the dendrites.
15-17
Currently, monoamine reuptake inhibitors have been used 
as antidepressants for the treatment of depression. In particu-
lar, venlafaxine is used as the inhibitor of both serotonin and 
norepinephrine. The primary function of venlafaxine is to pro-
tect the transport of serotonin and norepinephrine at the syn-
apse, thus increasing the concentration of both monoamines 
within the synapse. However, even though the level of both 
monoamines in the synapse increase immediately after the ad-
ministration of venlafaxine, there is a 2- to 6-week delay in its 
antidepressant effects.
18 It has been suggested that this delay 
results from changes in postreceptor signaling
19-21 or interac-
tions with HSP70.
9,10
In the study presented here, we investigated mechanisms 
other than the monoamine system, such as receptors and trans-
porters of serotonin and norepinephrine, as the possible mech-
anisms of the antidepressant effect of venlafaxine in depres-
sion. More specifically, we evaluated the relationship between 
dexamethasone and venlafaxine, which affect the level of HSP 
70 expression in rat C6 glioma cells. These cells, which have 
high levels of GRs but lack serotonin and norepinephrine 
transporters, react to the antidepressant similarly in vivo and 
in vitro by, for example, exhibiting an increase in adenylyl cy-
clase activity.
22-24 The expression of HSP70 was investigated 
using immunoblotting after groups of rat C6 glioma cells 
were each treated with 1) with dexamethasone only, 2) ven-
lafaxine only, 3) with simultaneous venlafaxine and dexa-
methasone, or 4) dexamethasone after venlafaxine pretreat-
ment. The objective of the third procedure was to determine 
the effect of venlafaxine on HSP70 under conditions of clini-
cal depression, and the objective of last procedure was to de-
termine the prophylactic effect of venlafaxine treatment on 
HSP70 under the conditions of depression.
Methods
Materials
Rat C6 glioma cells were obtained from ATCC (Manassas, 
VA, USA), dexamethasone was obtained from Sigma-Aldrich 
(St. Louis, MO, USA), and the antibody for HSP70 was ob-
tained from Santa Cruz Biotechnology (Santa Cruz, CA, USA). 
Venlafaxine was provided by Wyeth Korea (Seoul, Korea). 
All other chemicals were purchased from Sigma-Aldrich.
Cell cultures and reagent treatments
C6 glioma cells were cultivated in Dulbecco’s modified es-
sential medium (DMEM)(Gibco BRL, Gaithersburg, MD, 
USA) containing 10% fetal bovine serum (Gibco BRL) in a 
5% CO2 cultivator at 37℃. The DMEM culture medium was 
changed every 48 hours and cells were cultivated to the sta-
ble growth stage. Dexamethasone was dissolved in 95% eth-
anol to a concentration of 2.55 mM and then stored at -20℃. 
The ethanol in 0.25 mL of stored solution was evaporated in 
Nunc-Immuno plates (Vangard International, Neptune, NJ, 
USA) just before the experiment. Venlafaxine was dissolved 
into a mixture of 10% ethanol and sterilized water, filtered, 
and then diluted prior to use. The concentrations of dexameth-
asone (10 μM) and venlafaxine (10 μM) were set at optimal 
points at which it is know that apoptosis does not occur, as de-
termined in preliminary cultivating experiments
25-27 using vari-
ous concentrations of the drugs (5, 10, 50, and 100 μM). Each 
of the following procedures was repeated six times.
To enable determination of the expression of HSP70 in the 
rat C6 glioma cells after treatment with dexamethasone, the 
culture solution was replaced with a new solution containing 
dexamethasone (10 μM) when the cells in the incubator showed 
85% growth. The cells were treated with dexamethasone for 
6 hours and the expression of HSP70 was measured using an 
anti-SP70 monoclonal antibody (anti-HSP70mAb).
To investigate the effect of venlafaxine treatment on HSP70 
expression, the culture solution was replaced with one that 
contained only venlafaxine (10 μM) when the cells showed 
85% growth. Each group was treated for 1, 6, 24, and 72 hours. 
The expression of HSP70 at each of these time points was 
investigated using anti-HSP70mAb. The effects of simulta-
neous treatment with venlafaxine and dexamethasone were 
determined by replacing the culture solution with one contain-
ing venlafaxine (10 μM) and dexamethasone (10 μM) when 
the cell showed 85% growth. Each group was treated for 1, 6, 
24, and 72 hours. The expression of HSP70 at each of these 
time points was determined using anti-HSP70mAb.
The effects of pretreatment with venlafaxine on the action 
of dexamethasone were determined by first replacing the cul-
ture medium with one containing venlafaxine (10 μM) and 
incubation them for 1, 6, 24, and 72 hours. The culture medi-
um was then replaced with one containing dexamethasone J Yu et al. 
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(10 μM) and treated for a further 6 hours. The expression of 
HSP70 was then evaluated as before.
Protein extraction
Cells were washed in a 100-mm-diameter dish with phos-
phate-buffered saline and then gathered by centrifugation at 
2,000-3,000 rpm for 5 min. A 400-μL volume of Pro-Prep (iN-
tRon Biotechnology, Seongnam, Korea) was added to sam-
ples of 5×10
6 cells and the suspension stirred thoroughly. 
Cells were dissolved in ice for 20 min and the suspension then 
centrifuged again at 13,000 rpm at 4℃ for 5 min. The result-
ing supernatant was poured into a 1.5-mL tube and stored at 
-20℃ until protein quantification and immunoblotting.
Protein quantification
The concentration of proteins in each sample was meas-
ured using Bradford’s method (Bio-Rad Protein Assay Kit, Bio-
Rad Laboratories, Hercules, CA, USA). A working solution 
was made from diluted Bradford reagent in distilled water at 
a ratio of 1 : 5. We prepared 10 μL aliquots of 1, 0.5, 0.1, 0.05, 
0.01, and 0 mg/mL of bovine serum albumin standard, poured 
each standard into 96-well plates, and then added 200 μL of 
working solution. After leaving the solution at room temper-
ature for 5 min, absorbance was measured on an enzyme-linked 
immunosorbent assay reader at a wavelength of 595 nm. Pro-
tein concentration was then estimated using a standard curve.
Western blot analysis
Immunoblotting was performed to determine HSP70 ex-
pression by using anti-HSP70mAb against cell extracts. The 
same amount of protein was added to Laemmli sample buf-
fer [62.5 mM Tris-HCl, pH 6.8; 2% sodium dodecyl sulfate 
(SDS); 10% glycerol; 0.5% β-mercaptoethanol; and 10 μg/mL 
bromophenol blue], and the proteins were denatured by boil-
ing for 5 min. Each protein was separated on a 10% polyacryl-
amide gel using SDS-polyacryamide gel electrophoresis, and 
then electrotransferred onto nitrocellulose membranes. After 
blocking with 5% nonfat dry milk in Tris-buffered saline Tween 
20 (TBST) solution (20 mM Tris-HCl, pH 7.6; 500 mM NaCl; 
and 0.1% Tween 20), the membranes were incubated with 200 
μg/mL of anti-HSP70mAb (diluted to 1 : 2000) at room tem-
perature for 60 min, followed by horseradish-peroxidase-con-
jugated antimouse IgG (diluted to 1 : 1000) for 60 min. After 
washing twice in TBST (15 min each), the reactions were de-
tected using an enhanced chemiluminescence detection sys-
tem (Amersham Life Science, Buckinghamshire, UK). The 
concentration of HSP70 was quantified with QuantityOne soft-
ware (Bio-Rad Laboratories).
Statistical analysis
Data were expressed as mean±standard error of measure-
ment (SEM) values, and the level of statistical significance 
was set at p<0.05. The analyses were performed using the 
Statistical Package for the Social Sciences (SPSS) 12.0 for 
Windows (SPSS, Chicago, IL, USA). Analysis of variance 
was used to distinguish the different patterns of HSP70 expres-
sion according to chemical treatments. The degree of statisti-
cal significance between groups was investigated using 
paired-samples t-tests.
Results
Effect of dexamethasone on the expression 
of HSP70
The expression of HSP70 was slightly lower in the dexa-
methasone-treated group than in the control group, but the dif-
ference was not statistically significant (Figure 1).
Effect of venlafaxine on the expression of HSP70
The expressions of HSP70 in the experimental group were 
significantly higher 1 hour after treatment with venlafaxine 
compared to the control group (p=0.027). The expression of 
HSP70 tended to decrease after 24 hours (Figure 2).
Effects of simultaneous treatment with 
venlafaxine and dexamethasone 
on the expression of HSP70
Simultaneous treatment with venlafaxine and dexametha-
sone for 1 hour resulted in an increase in the expression of HSP 
70 compared to controls. However, the expression of HSP70 
decreased dramatically thereafter with time, so that after 72 
hours of treatment the expression of HSP70 had significantly 
decreased compared to the control group (p=0.001)(Figure 3).
Effect of dexamethasone on the expression 
of HSP70 in venlafaxine-pretreated cells
The effect of dexamethasone on the expression of HSP70 
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Figure 1. Effect of dexamethasone on HSP70 expression in rat 
C6 glioma cells. Cells were treated with dexamethasone for 6 
hours. There was no difference in the extent of HSP70 expression 
between control and the dexamethasone-treated group. Values of 
HSP70 density are represented as the mean±SEM (n=6) of the 
percent change from 100% control group. HSP70: heat shock pro-
tein 70, SEM: standard error of measurement.
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was dependent on the duration of venlafaxine pretreatment. 
For the groups pretreated with venlafaxine for 1 and 6 hours, 
no significant differences in HSP70 expression were observed 
compared to the control. On the other hand, groups that were 
pretreated with venlafaxine for 24 hours (p=0.003) and 72 
hours (p=0.002) exhibited a significant reduction in HSP70 
expression by dexamethasone compared to the control group 
(Figure 4).
Discussion
The two main findings of this study are as follows: 1) HSP 
70 expression increases soon after venlafaxine treatment, 
with or without dexamethasone treatment; and 2) simultane-
ous treatment with dexamethasone and venlafaxine or treat-
ment with dexamethasone following pretreatment with ven-
lafaxine results in a subsequent reduction in HSP70 expression.
The early increase in HSP70 expression found in this study 
(after 1 hour of treatment) is pertinent to several recent stud-
ies that showed tricyclic antidepressant-induced apoptosis in 
many cells.
28-30 
One of the selective serotonin reuptake inhibitors, fluox-
etine, also induces apoptosis in C6 glioma cells.
28 The results 
of our study raise the possibility that venlafaxine is a stressor 
in the early stage of treatment (1 hour), even though it has been 
shown that it does not induce apoptosis at the low concentra-
tions used in this study.
The design of our study did not allow us to determine the 
factor responsible for the decline of HSP70. Further research 
is required to determine the exact cause of the lowered HSP70 
expression. However, there are a few possible mechanisms 
that could underlie a reduction in HSP70 expression induced 
by the chronic administration of the antidepressant venlafax-
ine. Firstly, venlafaxine may reduce the activity of HSF by 
inducing mitogen-activated protein kinase (MAPK). Some 
studies
31,32 have shown that MAPK is a negative regulator of 
HSF, and another
33 has shown that extracellular signal-regu-
lated kinase, which is one of the MAPKs, inactivates HSF. 
Khawaja et al.
27 reported increases in the activity of MAPK 
200
150
100
50
0
Control           1 hr               6 hr             24 hr             72 hr
Control              1 hr             6 hr             24 hr             72 hr
Venlafaxine treatment duration
Venlafaxine treatment duration
Figure 2. Effect of venlafaxine on HSP70 expression in rat C6 
glioma cells. Cells were treated with venlafaxine for 1, 6, 24, and 
72 hours, whereas the control group was not treated with venla-
faxine. Complared to the control group, 1 hour treatment of venla-
faxine showed significantly increased expressions of HSP70. Val-
ues of HSP70 density are represented as the mean±SEM (n=6) 
of the percent change from 100% control group. *p<0.05 in com-
parison to the control group. HSP70: heat shock protein 70, SEM: 
standard error of measurement.
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Figure 3. Effect of simultaneous treatment with venlafaxine and 
dexamethasone on HSP70 expression in rat C6 glioma cells. Cells 
were treated with venlafaxine and dexamethasone for 1, 6, 24, 
and 72 hours, whereas the control group was treated neither with 
venlafaxine nor with dexamethasone. Compared to the control 
group, 72 hours treatment of venlafaxine and dexamethasone 
group showed significantly decreased expressions of HSP70. Val-
ues of HSP70 density are represented as the mean±SEM (n=6) 
of the percent change from 100% control group. *p<0.05 in compa-
rison to the control group. HSP70: heat shock protein 70, SEM: st-
andard error of measurement.
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Figure 4. Effect of dexamethasone on HSP70 expression in ven-
lafaxine-pretreated rat C6 glioma cells. Cells were pretreated with 
venlafaxine for 1, 6, 24, and 72 hours, and then treated with dexa-
methasone for 6 hours. 0 hr group was treated only with dexa-
methasone for 6 hours. Compared to the control group, the groups 
which were pretreated with venlafaxine for 24 and 72 hours showed 
significantly decreased expressions of HSP70. Values of HSP70 
density are represented as the mean±SEM (n=6) of the percent 
change from 100% control group. *p<0.05 in comparison to the 
control group. HSP70: heat shock protein 70, SEM: standard error 
of measurement.
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pathways such as p90 ribosomal S6 kinase (p90Rsk), phos-
phorylated cyclic AMP response element-binding protein, 
and phosphorylated ELK-1 after 3 days of treatment with ven-
lafaxine in C6 glioma cells. Therefore, the venlafaxine-in-
duced increased activity of MAPK pathways may inhibit HSF 
activity and result in a reduction of HSP70 expression. Sec-
ondly, venlafaxine induces the translocating mechanism of 
GRs and the resultant decrease in HSP70 expression. Various 
types of antidepressant, such as fluoxetine, milnacipran, and 
clogyline, are known to cause GR translocation.
34 Transloca-
tion of GRs into the nucleus inhibits the activity of HSF. The 
level of HSP70 expression could be decreased by the nega-
tive feedback of inhibiting trimerization of HSF in the pro-
cess of GR translocation.
Three recent studies involving various rat tissues
27,35,36 sup-
port the antidepressant effect of venlafaxine, and also suggest 
several mechanisms of action. The findings of one of those 
studies suggest that some of the centrally mediated benefits 
of venlafaxine in depression are due to its intracellular proper-
ties, especially on the neuroglial circuitry and MAPK/p90Rsk-
dependent pathways at an early stage.
27 One of the other stud-
ies has suggested that quetiapine and venlafaxine both target 
the hippocampus of stressed rats by enhancing hippocampal 
resilience, which may be impaired in patients with schizophre-
nia or depression.
35
In summary, the intracellular action of the antidepressant ven-
lafaxine was studied in rat C6 glioma cells using HSP70 im-
munocytochemistry and HSP70 Western blots; HSP70 is known 
to be associated with stress and depression. We observed that 
the application of 10 μM dexamethasone for 6 hours did not 
affect the level of HSP70 expression relative to control. This 
finding was contrary to our expectations and is inconsistent 
with a previous report concluding that dexamethasone is an 
inducer of the heat shock response.
37 Short-term (1 hour) treat-
ment with venlafaxine significantly increased the level of HSP 
70 expression, whereas long-term (72 hours) simultaneous tr-
eatment with venlafaxine and dexamethasone significantly 
reduced. 
Venlafaxine increases the expression of HSP70 in the short 
term, which might be due to it acting as a stressor. However, 
prolonged treatment with dexamethasone suppresses the ex-
pression of HSP70, possibly due to the induction of MAPK and 
GR translocation.
An in vivo experiment is needed to validate the results of 
this study. Nevertheless, this work represents an important in 
vitro model that could be used to screen potential novel anti-
depressants. Such a model would considerably benefit the field 
and also attempts by the drug industry to identify such com-
pounds. The present study suggests that the treatment of de-
pression with venlafaxine plays a role in preventing stress, and 
provides fundamental data to explain the pathophysiological 
mechanisms underlying depression.
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